Opendata, web and dolomites


Ultra-small implanted neurostimulation device for the treatment of Obstructive Sleep Apnea

Total Cost €


EC-Contrib. €






 Nyxoah project word cloud

Explore the words cloud of the Nyxoah project. It provides you a very rough idea of what is the project "Nyxoah" about.

trials    disorder    neurostimulation    heart    agencies    keep    reimbursement    patch    2009    prevalent    clinical    performance    surgery    lower    responds    public    loop    feedback    disposable    cardiovascular    uncomfortable    activation    attack    smaller    obese    drawbacks    invasive    plan    nerve    therapeutic    physicians    depression    pulse    regualatory    implant    social    detects    noisy    chip    economic    people    synced    neurostimulator    resistance    app    security    arrhythmia    impacts    closed    mask    disruptive    line    annual    nyxoah    wirelessly    ineffective    disease    compliance    powered    founded    pressure    sleepiness    smart    100m    sleep    device    efficacy    tissue    50    worldwide    elderly    fail    risk    company    lifelong    linked    continue    poor    apnea    refuse    healthcare    mortality    cohorts    morbidity    outright    world    monitoring    displays    tells    stuck    stroke    constant    cpap    machine    attached    communicates    chronic    outcome    infection    adjust    obstructive    neurocognitive    150b    first    options    acute    burnout    implanted    unpleasant    standards    industrialization    patients    implantations    chin    cardiac    patient    treatment    daytime    tiny    central    health    cloud   

Project "Nyxoah" data sheet

The following table provides information about the project.


Organization address
postcode: 1435
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2016-09-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NYXOAH SA BE (MONT-SAINT-GUIBERT) coordinator 50˙000.00


 Project objective

Obstructive Sleep Apnea is the world's most common sleep disorder and affects 100m people worldwide. It is particularly prevalent among elderly and obese cohorts and is a lifelong disease, with acute and chronic health impacts. It is linked to increased cardiovascular morbidity and mortality, and associated with increased risk of heart attack, cardiac arrhythmia, stroke, daytime sleepiness, depression and poor neurocognitive performance. Estimated annual economic costs of the disease are €60-150b. Established therapeutic options are uncomfortable with unpleasant side effects and/or ineffective; they can also require invasive surgery. Compliance is a major problem with the first line treatment, CPAP: 50% of users refuse it outright or fail to continue use after 1 year. Nyxoah's disruptive neurostimulation device responds directly to these needs and drawbacks. Central to the system is a tiny device implanted under the chin that - compared to other neurostimulator implantations - is smaller, less invasive and has lower risk of infection. The device is powered wirelessly by an activation chip, which is attached to a disposable smart patch and stuck under the chin before sleep. No mask, no noisy machine, no unpleasant side effects. The chip has a closed feedback loop with the implant, which detects tissue resistance and tells the chip to adjust the pulse to keep constant pressure on the nerve, to avoid burnout; it also communicates wirelessly with an app, which displays useful information (synced with the cloud) for use by patients, physicians and social security agencies; this is a key development to allow treatment compliance monitoring and therefore for reimbursement. During the Phase 1 project, the company, founded in 2009, will assess scale-up industrialization plan, product development according to regualatory standards and clinical trials to be deployed in Europe to show the system efficacy on patient outcome and public healthcare costs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NYXOAH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NYXOAH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)


CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More  

ImmuneHunter (2017)

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Read More